Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

UroGen Pharma (URGN) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $4.5 million.

  • UroGen Pharma's Accumulated Depreciation & Amortization rose 712.08% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 712.08%. This contributed to the annual value of $4.3 million for FY2024, which is 832.49% up from last year.
  • UroGen Pharma's Accumulated Depreciation & Amortization amounted to $4.5 million in Q3 2025, which was up 712.08% from $4.4 million recorded in Q2 2025.
  • UroGen Pharma's Accumulated Depreciation & Amortization's 5-year high stood at $4.5 million during Q3 2025, with a 5-year trough of $200000.0 in Q1 2021.
  • Over the past 5 years, UroGen Pharma's median Accumulated Depreciation & Amortization value was $3.6 million (recorded in 2023), while the average stood at $3.2 million.
  • In the last 5 years, UroGen Pharma's Accumulated Depreciation & Amortization soared by 191300.0% in 2021 and then soared by 682.21% in 2025.
  • Over the past 5 years, UroGen Pharma's Accumulated Depreciation & Amortization (Quarter) stood at $2.2 million in 2021, then skyrocketed by 41.51% to $3.2 million in 2022, then rose by 25.46% to $4.0 million in 2023, then rose by 8.32% to $4.3 million in 2024, then rose by 5.42% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $4.4 million for Q2 2025, and $4.4 million during Q1 2025.